Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment

被引:9
|
作者
Gouw, S. C. [1 ,2 ]
Ter Avest, P. C. [1 ]
Van Helden, P. M. [3 ,4 ]
Voorberg, J. [3 ,4 ]
Van Den Berg, H. M. [1 ,5 ]
机构
[1] Univ Med Ctr Utrecht, Creveldklin, Dept Pediat, NL-3508 GA Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Pediat, NL-3508 GA Utrecht, Netherlands
[3] AMC Sanquin Res, Dept Plasma Prot, Van Creveld Lab, Amsterdam, Netherlands
[4] AMC Sanquin Res, Landsteiner Lab, Amsterdam, Netherlands
[5] Univ Med Ctr Utrecht, Dept Lab Med, Utrecht, Netherlands
关键词
factor VIII inhibitors; IgG subclasses; immune tolerance induction; intensity of treatment; rituximab; IMMUNE TOLERANCE INDUCTION; PREVIOUSLY UNTREATED PATIENTS; FACTOR-VIII INHIBITORS; IGG SUBCLASSES; RISK-FACTORS; POLYMORPHISMS; CHILDREN; GENE;
D O I
10.1111/j.1365-2516.2009.01998.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Both genetic factors and environmental factors are suggested to play a role in the aetiology of inhibitor development in patients with severe haemophilia A. Monozygotic twins are ideal candidates to study the influence of environmental factors. We describe a pair of 3-year-old monozygotic twin brothers with severe haemophilia A. Prenatal diagnosis confirmed the presence of an intron 22 inversion. Other patient-related factors such as birth weight, vaccinations and the duration of breastfeeding were similar. At the age of 7 months, one boy suffered from a spontaneous subdural haematoma, which needed complete correction of haemostasis with continuous infusion of a third-generation recombinant factor VIII. A persistent high-titre inhibitor with severe clinical symptoms developed, that could only be eradicated with high-dose immune tolerance induction (ITI) for 36 months in combination with rituximab therapy. His twin brother first received treatment at 9 months of age with the same FVIII product. After treatment on nine exposure days, he developed a low-titre inhibitor at the age of 14.5 months. Unlike his brother, he was tolerized without difficulties with low-dose ITI within 2 months. The discordant antibody responses were underlined by dissimilar IgG1 and IgG4 levels in their plasma. The discordant immune response to FVIII in this pair of monozygotic twin brothers seemed to be related to intensity of treatment and severity of bleeds. This confirms that these environmental factors play an additional role in the development of inhibitors.
引用
收藏
页码:712 / 717
页数:6
相关论文
共 47 条
  • [31] Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: Potential relevance of antibody titers in monitoring treatment response
    Lorenzo, Bresciani
    Alessandro, Salvalaggio
    Elisa, Vegezzi
    Andrea, Visentin
    Andrea, Fortuna
    Mariagiulia, Anglani
    Mario, Cacciavillani
    Masciocchi, Stefano
    Scaranzin, Silvia
    Miryam, Carecchio
    Andrea, Martinuzzi
    Matteo, Gastaldi
    Chiara, Briani
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2023, 28 (03) : 522 - 527
  • [32] Fatty acid binding proteins as biomarkers of disease severity and response to treatment in severe pneumonia required admission to intensive care unit
    Tsai, Han-Chen
    Chang, Shi-Chuan
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (20)
  • [33] CLINICAL AND MRI PREDICTIVE FACTORS OF SIGNIFICANT RESPONSE TO A TREATMENT COUPLING CAPSULAR DISTENSION AND INTENSIVE REHABILITATION IN PATIENTS WITH SEVERE ADHESIVE CAPSULITIS
    Hamroun, S.
    Cinotti, V.
    Mihoubi-Bouvier, F.
    Garofoli, R.
    Couraud, G.
    Boisson, M.
    Roren, A.
    Nguyen, C.
    Feydy, A.
    Guerini, H.
    Rannou, F.
    Drape, J. L.
    Colau, M. M. Lefevre
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1925 - 1926
  • [34] A CASE OF SEVERE OPTIC NEUROPATHY CAUSED BY BIOPSY PROVEN CLL WITHOUT PERIPHERAL TRANSFORMATION WITH EXCELLENT TREATMENT RESPONSE TO RITUXIMAB, OBINUTUZUMAB (SECOND GENERATION ANTI-CD20 MONOCLONAL ANTIBODY) AND CHLORAMBUCIL
    Jhaveri, Divita
    Swayne, Andrew
    Brown, Helen
    Airey, Caroline
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 (05):
  • [35] UPDATE IN INTENSIVE CARE MEDICINE: SERIOUS MULTIRESISTANT GRAM-NEGATIVE INFECTIONS Treatment of severe infections caused by ESBL or carbapenemases-producing Enterobacteriaceae
    Lombardi, G.
    Tanzarella, E. S.
    Cutuli, S. L.
    De Pascale, G.
    MEDICINA INTENSIVA, 2023, 47 (01) : 34 - 44
  • [36] Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody
    Gottlieb, AB
    Lebwohl, M
    Totoritis, MC
    Abdulghani, AA
    Shuey, SR
    Romano, P
    Chaudhari, U
    Allen, RS
    Lizambri, RG
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (05) : 692 - 700
  • [37] Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris
    Gottlieb, AB
    Masud, S
    Ramamurthi, R
    Abdulghani, A
    Romano, P
    Chaudhari, U
    Dooley, LT
    Fasanmade, AA
    Wagner, CL
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 48 (01) : 68 - 75
  • [38] Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency
    Carbone, J
    Escudero, A
    Mayayo, M
    Ballesteros, M
    Perez-Corral, A
    Sanchez-Ramon, S
    Sarmiento, E
    Micheloud, D
    Fernandez-Cruz, E
    AUTOIMMUNE DISEASES AND TREATMENT: ORGAN-SPECIFIC AND SYSTEMIC DISORDERS, 2005, 1051 : 666 - 671
  • [39] Analysis of the diversity of antibody response towards AAV8 capsid protein over time following a single administration of scAAV2/8-LP1-hFIXco in subjects with severe haemophilia B
    Dane, A. P.
    Rosales, C.
    Tseng, Y.
    McIntosh, J. H.
    McKenna, R.
    Agbandje-McKenna, M.
    Davidoff, A. M.
    Nathwani, A. C.
    HUMAN GENE THERAPY, 2017, 28 (12) : A104 - A105
  • [40] Combined treatment of sequential intensive immunosuppressive therapy and hematopoietic growth factors in patients with severe aplastic anemia: long-term outcome of hematopoietic recovery response
    Song, Yan
    Wang, Huaquan
    Liu, Chunyan
    Shao, Zonghong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (11): : 12347 - 12353